Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (Becton, Dickinson and Company) has appointed Francesca DeMartino as senior vice president of investor relations, effective Nov. 29. DeMartino will oversee the communication of the BD2025 strategy to investors, focusing on shareholder value. She brings over 20 years of experience in investor relations from notable companies, including Medtronic, where her team won awards for investor relations. DeMartino succeeds Kristen Stewart, who moves to a new role within the company.
BD (Becton, Dickinson and Company) hosted its Investor Day on Nov. 12, 2021, focusing on its BD 2025 strategy to drive growth through innovation and operational simplification. The company aims for a long-term compound annual revenue growth of 5.5% or more, with double-digit EPS growth and increasing dividends. Key initiatives include organic and inorganic investments, reshaping the innovation pipeline with higher-margin products, and enhancing margins through simplification programs. BD emphasizes disciplined capital deployment to balance growth investments and shareholder returns.
QIAGEN N.V. (NYSE: QGEN) and Becton, Dickinson and Company (NYSE: BDX) have settled a patent infringement lawsuit concerning QIAGEN’s NeuMoDx™ PCR systems. The settlement, resolving all claims, mandates a one-time payment of $53 million to BD. Notably, this agreement does not alter QIAGEN's expected net sales or adjusted earnings outlook for Q4 and full-year 2021. QIAGEN continues to offer innovative solutions for molecular diagnostics.
BD (Becton, Dickinson and Company) reported strong fiscal 2021 results, with Q4 revenues reaching $5.135 billion, a 7.3% increase year-over-year. Diluted EPS was $0.84, up 133.3%. The company achieved revenue growth across segments, led by BD Medical's 9.2% rise. Despite a decline in COVID-19 diagnostic revenue, BD's outlook for fiscal 2022 anticipates revenue between $19.3 billion and $19.5 billion and adjusted EPS of $12.30 to $12.50, reflecting 5-6% growth. BD also increased its dividend by 4.8% and repurchased 3 million shares for $750 million.
The Board of Directors of BD (Becton, Dickinson and Company) declared a quarterly dividend of $0.87 per share, up 4.8% from the previous quarter, payable on December 31, 2021. This marks the 50th consecutive year of dividend increases, reinforcing BD's status in the S&P 500 Dividend Aristocrats Index. Additionally, the board authorized a share repurchase of up to 10 million shares, adding to the remaining 750,000 shares from a previous program. This strategic move is aimed at enhancing shareholder value, aligned with the company's 2025 strategy.
BD (Becton, Dickinson and Company) has announced a strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop a suite of COVID-19 combination diagnostic tests. This collaboration will receive initial funding of $24.7 million, potentially extending to $40.3 million. The new tests aim to simultaneously detect multiple respiratory pathogens, enhancing patient management and healthcare resource allocation. BD plans to achieve full FDA clearance for these tests, ensuring their availability even post-COVID-19 emergency.
BD (Becton, Dickinson and Company) will hold a virtual investor day on November 12, 2021, starting at 8 a.m. The event, lasting approximately four hours, will feature presentations from CEO Tom Polen and the executive leadership team, followed by Q&A sessions. A replay and additional materials will be available on BD's investor page after the event. BD is a global leader in medical technology, committed to enhancing healthcare through innovative solutions. For more information, visit bd.com.
BD (Becton, Dickinson and Company) has announced the shipment of its first over-the-counter (OTC) COVID-19 rapid antigen test, utilizing smartphone computer vision technology for result interpretation. Available for $39.99 with promotional pricing at $26.50 on Amazon, the BD Veritor™ test offers digital results in 15 minutes, simplifying at-home testing. It features automated reporting to health agencies and is suitable for individuals aged 14 and older. Authorized under Emergency Use Authorization, the test addresses common at-home testing challenges, including result interpretation and reporting.
BD (Becton, Dickinson and Company) announced the appointment of Dr. Carrie L. Byington to its board of directors, increasing the board to 13 members. Byington is the executive vice president and head of University of California Health, leading a $20 billion academic health system. Her experience includes significant roles at Texas A&M University and the University of Utah. The company views her appointment as timely, aligning with its BD 2025 strategy aimed at innovating in connected care and improving chronic disease outcomes.
On October 18, 2021, BD (Becton, Dickinson and Company) announced its new ESG strategy, Together We Advance, aimed at enhancing its commitment to health, community, and environmental stewardship. This strategy focuses on four pillars: Company Health, Planet Health, Community Health, and Human Health. BD set ambitious 2030 goals, including a 46% reduction in Scope 1 and 2 greenhouse gas emissions and carbon neutrality in direct operations by 2040. The strategy emphasizes climate change, responsible supply chains, and transparency, while aligning with the UN Sustainable Development Goals.